Back to top

Compass new data validates COMP360 durability profile, says Morgan Stanley

Morgan Stanley notes that Compass Pathways (CMPS) reported COMP006 Part B 26-week data from its second Phase 3 pivotal trial of COMP360 in treatmen...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

COMPASS Pathways PLC Sponsored ADR (CMPS)